KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $251.1 million.

  • Alnylam Pharmaceuticals' Consolidated Net Income rose 32504.62% to $251.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 11311.16%. This contributed to the annual value of -$278.2 million for FY2024, which is 3681.73% up from last year.
  • Latest data reveals that Alnylam Pharmaceuticals reported Consolidated Net Income of $251.1 million as of Q3 2025, which was up 32504.62% from -$66.3 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Consolidated Net Income's 5-year high stood at $251.1 million during Q3 2025, with a 5-year trough of -$405.9 million in Q3 2022.
  • For the 5-year period, Alnylam Pharmaceuticals' Consolidated Net Income averaged around -$135.5 million, with its median value being -$174.1 million (2023).
  • Data for Alnylam Pharmaceuticals' Consolidated Net Income shows a peak YoY increase of 32504.62% (in 2025) and a maximum YoY decrease of 29242.7% (in 2025) over the last 5 years.
  • Over the past 5 years, Alnylam Pharmaceuticals' Consolidated Net Income (Quarter) stood at -$258.5 million in 2021, then grew by 19.72% to -$207.5 million in 2022, then surged by 33.55% to -$137.9 million in 2023, then surged by 39.24% to -$83.8 million in 2024, then surged by 399.76% to $251.1 million in 2025.
  • Its Consolidated Net Income was $251.1 million in Q3 2025, compared to -$66.3 million in Q2 2025 and -$57.5 million in Q1 2025.